Abacavir Canon, 600 mg 30 pcs

Abacavir is a nucleoside analogue that inhibits HIV reverse transcriptase and selectively suppresses HIV-1 and HIV-2 replication, including HIV-1 strains resistant to zidovudine, lamivudine, zalcitabine, didanosine and nevirapine. Abacavir undergoes intracellular metabolism to the active form, carbovir-5′-triphosphate (carbovir-TF). According to in vitro studies, the antiviral effect of the drug is due to inhibition of HIV reverse transcriptase, which leads to cutting off DNA synthesis on RNA matrix and stopping HIV replication.

Indications

Treatment of HIV infection in adults and children weighing more than 14 kg as part of combination antiretroviral therapy.

Pharmacological effect

Abacavir is a nucleoside analogue that inhibits HIV reverse transcriptase and selectively inhibits the replication of HIV-1 and HIV-2, including HIV-1 strains resistant to zidovudine, lamivudine, zalcitabine, didanosine and nevirapine. Abacavir undergoes intracellular metabolism, turning into the active form, carbovir 5′-triphosphate (carbovir-TF). According to in vitro studies, the antiviral effect of the drug is due to the inhibition of HIV reverse transcriptase, which leads to the termination of DNA synthesis on the RNA template and stops HIV replication.

Special instructions

The drug should be prescribed by a doctor experienced in treating HIV infection.
Each patient should read the instructions for use.

Active ingredient

Abacavir

Composition

1 film-coated tablet 600 mg contains:

Contraindications

– Hypersensitivity to abacavir or any other component of the drug;
– Children weighing less than 14 kg (for this dosage form);
– Moderate and severe liver failure (class B and C on the Child-Pugh scale), due to the lack of clinical data and the recommended dosage regimen;
– Mild liver failure (class A on the Child-Pugh scale), due to the inability to provide the dosage regimen;
– Breastfeeding period;
– Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Side Effects

The nature of other adverse reactions other than HSR, but observed in patients taking Abacavir Canon, is not completely clear. Whether these adverse reactions are a consequence of the use of the drug Abacavir Canon or a wide range of other drugs simultaneously prescribed for the treatment of HIV infections, or whether they are caused by the disease itself, has not yet been established.

Interaction

In vitro studies and analysis of the major metabolic pathways of abacavir indicate that cytochrome P450-mediated interactions with other drugs are unlikely.

Overdose

Symptoms
In clinical studies, no adverse reactions were identified when using abacavir in single doses up to 1200 mg and daily doses up to 1800 mg. The effect of the drug in higher doses has not yet been studied.

Storage conditions

At a temperature not exceeding 25 °C in the manufacturer’s packaging.
Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Kanonpharma production CJSC, Russia